Erenumab Safe, Efficient, as Prophylactic for Episodic Migraine

BOSTON — Results from 2 phase 3 clinical trials presented at the American Headache Society (AHS) 56th Annual Scientific Meeting indicate that erenumab may represent a safe and efficacious prophylactic treatment for episodic migraine.

Erenumab, also known as AMG 334, is a fully human monoclonal antibody raised against the Calcitonin Gene-Related Peptide (CGRP) receptor, which, along with CGRP, has been implicated in the pathogenesis of migraine.

Continue reading at Neurology Advisor

Latest News